A Study Of PF-05212384 In Combination with Other Anti-Tumor Agents and in Combination with Cisplatin in Patients with Triple Negative Breast Cancer (TNBC) in an Expansion Arm

A Phase 1b Open-Label Three-Arm Multi-Center Study to Assess the Safety and Tolerability of PF-05212384 (PI3K/mTOR Inhibitor) in Combination with Other Anti-Tumor Agents

Category & Conditions:
Cancer
Medicine:
Gedatolisib (PF-05212384)
VIZIMPRO® TABLETS(DACOMITINIB)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B2151002
Open Plain Language Summary Result:Click here